Search results
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Zacks via Yahoo Singapore Finance· 3 hours agoThe company’s ENHANZE drug delivery technology helps in developing SC formulation of drugs. Several...
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
Zacks via Yahoo Singapore Finance· 5 hours agoLooking at individual holdings, Chevron Corporation (CVX) accounts for about 9.83% of total assets,...
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
Zacks via Yahoo Singapore Finance· 1 day agoEli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding...
Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value
GuruFocus.com via Yahoo Singapore Finance· 1 day agoIn this article, we will take a look into AbbVie Inc's (NYSE:ABBV) DCF analysis, a reliable and...
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Zacks via Yahoo Singapore Finance· 2 days agoThe traditional ways to plan for your retirement may mean income can no longer cover expenses...
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal
Reuters via Yahoo Singapore Finance· 2 days ago(Reuters) -Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on...
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
Zacks via Yahoo Singapore Finance· 2 days agoThe NYSE ARCA Pharmaceutical Index declined 1.67% in the last five trading sessions. In the last...
2 Boston Partners Mutual Funds for Maximum Returns
Zacks via Yahoo Singapore Finance· 5 days agoRamallo has been the lead manager of BPAVX since Dec 30, 2007. Most of the fund’s holdings were in companies like Johnson & Johnson (2.2%), JPMorgan...
AbbVie cuts 2024 profit forecast on R&D expenses
Reuters via Yahoo Singapore Finance· 7 days ago(Reuters) -AbbVie lowered its 2024 adjusted profit forecast on Wednesday, citing $937 million in milestones, and research and development expenses...